Ernexa Therapeutics Inc.
ERNA
$4.27
-$0.03-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -19.56% | 15.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.74% | 69.34% | |||
| Operating Income | -15.74% | -69.34% | |||
| Income Before Tax | 27.71% | -254.60% | |||
| Income Tax Expenses | -- | 35.48% | |||
| Earnings from Continuing Operations | 27.19% | -266.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.19% | -266.58% | |||
| EBIT | -15.74% | -69.34% | |||
| EBITDA | -15.74% | -70.01% | |||
| EPS Basic | 51.16% | -52.06% | |||
| Normalized Basic EPS | 22.58% | 8.44% | |||
| EPS Diluted | 51.16% | -52.06% | |||
| Normalized Diluted EPS | 22.58% | 8.44% | |||
| Average Basic Shares Outstanding | 49.37% | 139.78% | |||
| Average Diluted Shares Outstanding | 49.37% | 139.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||